Last reviewed · How we verify
NCT06758947: upadacetinib
Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF
Phase 3 trial testing Upadacitinib 15 MG in Interstitial Lung Disease Due to Systemic Disease (Disorder) in 60 participants. Completed in 15 November 2024.
15 June 2024
Quick facts
| Lead sponsor | Assiut University |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 15 January 2023 |
| Primary completion | 15 June 2024 |
| Estimated completion | 15 November 2024 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Upadacitinib 15 MG — full drug profile →
- Cellcept Oral Product
Conditions studied
- Interstitial Lung Disease Due to Systemic Disease (Disorder) — all drugs for Interstitial Lung Disease Due to Systemic Disease (Disorder) →
Sponsor
Assiut University
Who can join
Adults 18 to 65, any sex, with Interstitial Lung Disease Due to Systemic Disease (Disorder). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Systemic sclerosis (SSc) is a systemic autoimmune disease with heterogeneous clinical presentation and prognosis. JAK inhibitors reduced cutaneous and pulmonary fibrosis in mice models of SSc. Clinical data regarding the efficacy and safety of JAK inhibitors in SSc patients are scarce
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06758947
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Upadacitinib 15 MG
Trials testing the same drug.
- NCT06687551 — JAK Inhibitor Dose TAPering Strategy Study · Phase 4 · not yet recruiting
- NCT06454461 — Efficacy of Upadacitinib After NECS in Vitiligo · NA · recruiting
- NCT06379958 — Drug-Drug Interaction (DDI) Study of Leramistat in Healthy Adult Subjects · Phase 1 · recruiting
- NCT07080346 — Upadacitinib for Refractory Behcet's Syndrome · Phase 2 · completed
Other Assiut University trials
Trials by the same sponsor.
- NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
- NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
- NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
- NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
- NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06758947 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assiut University
- Last refreshed: 6 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06758947.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing